Which has stronger earnings and valuation, JSPR or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A XBiotech N/A N/A -$45.54M -$1.48 N/A

Is JSPR or XBIT more profitable?

XBiotech's return on equity of -31.62% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% XBiotech N/A -31.62% -30.29%

Is GANX or JSPR more profitable?

Gain Therapeutics' return on equity of -161.59% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Jasper Therapeutics N/A -884.17% -143.83%

Does the media prefer GANX or JSPR?

In the previous week, Jasper Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Jasper Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Jasper Therapeutics' score of 0.47 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, JSPR or RNTX?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is JSPR or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Rein Therapeutics N/A N/A -63.69%

Do analysts prefer APLM or JSPR?

Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,363.74%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has stronger valuation and earnings, APLM or JSPR?

Apollomics has higher revenue and earnings than Jasper Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.37 -$10.94M N/A N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is APLM or JSPR more profitable?

Apollomics' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Jasper Therapeutics N/A -884.17% -143.83%

Which has higher earnings and valuation, JSPR or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.34 N/A

Is JSPR or ONCY more profitable?

Oncolytics Biotech's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Oncolytics Biotech N/A N/A -442.99%

Does the media refer more to JSPR or ONCY?

In the previous week, Oncolytics Biotech had 4 more articles in the media than Jasper Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for Jasper Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat Jasper Therapeutics' score of 0.47 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncolytics Biotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jasper Therapeutics (JSPR) Competitors

$0.50 +0.01 (+1.09%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$0.50 -0.01 (-1.00%)

As of 10/14/2026 07:56 PM Eastern

Compare

JSPR vs. XBIT, GANX, RNTX, APLM, and ONCY

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include XBiotech (XBIT), Gain Therapeutics (GANX), Rein Therapeutics (RNTX), Apollomics (APLM), and Oncolytics Biotech (ONCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to XBiotech?

Jasper Therapeutics (NASDAQ:JSPR) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Jasper Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

In the previous week, Jasper Therapeutics had 3 more articles in the media than XBiotech. MarketBeat recorded 4 mentions for Jasper Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.79 beat Jasper Therapeutics' score of 0.47 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
XBiotech	Very Positive

XBiotech's return on equity of -31.62% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
XBiotech	N/A	-31.62%	-30.29%

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 21.1% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jasper Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 1,363.74%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jasper Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XBiotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

Summary

Jasper Therapeutics beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Gain Therapeutics' return on equity of -161.59% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Gain Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 480.81%. Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,363.74%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Gain Therapeutics has higher revenue and earnings than Jasper Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,152.10	-$20.16M	-$0.50	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Jasper Therapeutics and 3 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.63 beat Jasper Therapeutics' score of 0.47 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gain Therapeutics beats Jasper Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Rein Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Rein Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Rein Therapeutics	N/A	N/A	-63.69%

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rein Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Jasper Therapeutics has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Jasper Therapeutics currently has a consensus target price of $7.33, indicating a potential upside of 1,363.74%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 923.89%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Jasper Therapeutics had 3 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Jasper Therapeutics and 1 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.82 beat Jasper Therapeutics' score of 0.47 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Rein Therapeutics	Very Positive

Summary

Jasper Therapeutics beats Rein Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Jasper Therapeutics had 3 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Jasper Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.79 beat Jasper Therapeutics' score of 0.47 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Jasper Therapeutics	Neutral

Apollomics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Jasper Therapeutics	N/A	-884.17%	-143.83%

Apollomics has higher revenue and earnings than Jasper Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.37	-$10.94M	N/A	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,363.74%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Apollomics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Jasper Therapeutics beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Oncolytics Biotech?

Jasper Therapeutics (NASDAQ:JSPR) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Jasper Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,363.74%. Oncolytics Biotech has a consensus price target of $5.00, suggesting a potential upside of 829.02%. Given Jasper Therapeutics' higher probable upside, equities research analysts clearly believe Jasper Therapeutics is more favorable than Oncolytics Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

In the previous week, Oncolytics Biotech had 4 more articles in the media than Jasper Therapeutics. MarketBeat recorded 8 mentions for Oncolytics Biotech and 4 mentions for Jasper Therapeutics. Oncolytics Biotech's average media sentiment score of 1.12 beat Jasper Therapeutics' score of 0.47 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncolytics Biotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jasper Therapeutics has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oncolytics Biotech's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Oncolytics Biotech	N/A	N/A	-442.99%

Summary

Oncolytics Biotech beats Jasper Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.49M	$3.84B	$7.19B	$13.18B
Dividend Yield	N/A	3.66%	2.52%	19.60%
P/E Ratio	-0.32	9.24	208.53	19.36
Price / Sales	N/A	1,136.73	557.56	74.68
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	3.34	16.54	10.51	5.92
Net Income	-$75.80M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-10.54%	-5.80%	-3.49%	-3.85%
1 Month Performance	-12.11%	-12.84%	-7.76%	-6.37%
1 Year Performance	-80.73%	3.05%	0.82%	-6.01%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	1.9541 of 5 stars	$0.50 +1.1%	$7.33 +1,363.7%	-80.0%	$16.49M	N/A	N/A	22	Analyst Forecast Gap Up
XBIT XBiotech	1.39 of 5 stars	$2.27 -1.1%	N/A	-13.9%	$69.12M	N/A	N/A	87	Positive News
GANX Gain Therapeutics	1.8711 of 5 stars	$1.53 -2.5%	$7.67 +401.1%	-35.3%	$66.90M	$50K	N/A	21
RNTX Rein Therapeutics	2.9046 of 5 stars	$0.77 -2.4%	$6.00 +683.3%	-56.3%	$66.51M	N/A	N/A	10	Positive News
APLM Apollomics	1.8255 of 5 stars	$22.35 +4.8%	N/A	+16.7%	$65.02M	$8.50M	N/A	15	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. XBIT, GANX, RNTX, APLM, and ONCY

How does Jasper Therapeutics compare to XBiotech?

Summary

How does Jasper Therapeutics compare to Gain Therapeutics?

Summary

How does Jasper Therapeutics compare to Rein Therapeutics?

Summary

How does Jasper Therapeutics compare to Apollomics?

Summary

How does Jasper Therapeutics compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. XBIT, GANX, RNTX, APLM, and ONCY

How does Jasper Therapeutics compare to XBiotech?

Which has more risk and volatility, JSPR or XBIT?

Does the media refer more to JSPR or XBIT?

Is JSPR or XBIT more profitable?

Do institutionals & insiders have more ownership in JSPR or XBIT?

Do analysts rate JSPR or XBIT?

Which has stronger earnings and valuation, JSPR or XBIT?

Summary

How does Jasper Therapeutics compare to Gain Therapeutics?

Is GANX or JSPR more profitable?

Do analysts prefer GANX or JSPR?

Which has better valuation & earnings, GANX or JSPR?

Do institutionals and insiders hold more shares of GANX or JSPR?

Which has more risk and volatility, GANX or JSPR?

Does the media prefer GANX or JSPR?

Summary

How does Jasper Therapeutics compare to Rein Therapeutics?

Is JSPR or RNTX more profitable?

Do institutionals & insiders have more ownership in JSPR or RNTX?

Which has better valuation & earnings, JSPR or RNTX?

Which has more volatility and risk, JSPR or RNTX?

Do analysts prefer JSPR or RNTX?

Does the media refer more to JSPR or RNTX?

Summary

How does Jasper Therapeutics compare to Apollomics?

Does the media favor APLM or JSPR?

Is APLM or JSPR more profitable?

Which has stronger valuation and earnings, APLM or JSPR?

Do analysts prefer APLM or JSPR?

Which has more risk & volatility, APLM or JSPR?

Do insiders & institutionals hold more shares of APLM or JSPR?

Summary

How does Jasper Therapeutics compare to Oncolytics Biotech?

Do analysts recommend JSPR or ONCY?

Which has higher earnings and valuation, JSPR or ONCY?

Does the media refer more to JSPR or ONCY?

Which has more risk & volatility, JSPR or ONCY?

Do insiders and institutionals hold more shares of JSPR or ONCY?

Is JSPR or ONCY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools